AIMS/HYPOTHESIS: Individuals with impaired fasting glucose (IFG) are at increased risk of developing diabetes over the subsequent decade. However, there is uncertainty as to the mechanisms contributing to the development of diabetes. We sought to quantitate insulin secretion and action across the prediabetic range of fasting glucose. METHODS: We studied a cohort of 173 individuals with a fasting glucose concentration <7·0 mM after an overnight fast using a 75-g oral glucose tolerance test (OGTT). Insulin action (S(i)) was estimated using the oral glucose minimal model, and β-cell responsivity indices (φ) were estimated using the oral C-peptide minimal model. The disposition index (DI) for each individual was calculated. The relationship of DI, φ and S(i) with fasting and postchallenge glucose, as well as other covariates, was explored using a generalized linear regression model. RESULTS: In this cross-sectional study, S(i) and DI were inversely related to fasting glucose concentrations. On the other hand, φ was unrelated to fasting glucose concentrations. S(i), φ and DI were all inversely related to area above basal glucose concentrations after glucose challenge. Multiple parameters including body composition and gender contributed to the variability of S(i) and DI at a given fasting or postchallenge glucose concentration. CONCLUSIONS/ INTERPRETATION: Defects in insulin secretion and action interact with body composition and gender to influence postchallenge glucose concentrations. There is considerable heterogeneity of insulin secretion and action for a given fasting glucose likely because of patient subsets with isolated IFG and normal glucose tolerance.
AIMS/HYPOTHESIS: Individuals with impaired fasting glucose (IFG) are at increased risk of developing diabetes over the subsequent decade. However, there is uncertainty as to the mechanisms contributing to the development of diabetes. We sought to quantitate insulin secretion and action across the prediabetic range of fasting glucose. METHODS: We studied a cohort of 173 individuals with a fasting glucose concentration <7·0 mM after an overnight fast using a 75-g oral glucose tolerance test (OGTT). Insulin action (S(i)) was estimated using the oral glucose minimal model, and β-cell responsivity indices (φ) were estimated using the oral C-peptide minimal model. The disposition index (DI) for each individual was calculated. The relationship of DI, φ and S(i) with fasting and postchallenge glucose, as well as other covariates, was explored using a generalized linear regression model. RESULTS: In this cross-sectional study, S(i) and DI were inversely related to fasting glucose concentrations. On the other hand, φ was unrelated to fasting glucose concentrations. S(i), φ and DI were all inversely related to area above basal glucose concentrations after glucose challenge. Multiple parameters including body composition and gender contributed to the variability of S(i) and DI at a given fasting or postchallenge glucose concentration. CONCLUSIONS/ INTERPRETATION: Defects in insulin secretion and action interact with body composition and gender to influence postchallenge glucose concentrations. There is considerable heterogeneity of insulin secretion and action for a given fasting glucose likely because of patient subsets with isolated IFG and normal glucose tolerance.
Authors: Chiara Dalla Man; Marco Campioni; Kenneth S Polonsky; Rita Basu; Robert A Rizza; Gianna Toffolo; Claudio Cobelli Journal: Diabetes Date: 2005-11 Impact factor: 9.461
Authors: Robert A Ritzel; Alexandra E Butler; Robert A Rizza; Johannes D Veldhuis; Peter C Butler Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: Christian Meyer; Walkyria Pimenta; Hans J Woerle; Timon Van Haeften; Ervin Szoke; Asimina Mitrakou; John Gerich Journal: Diabetes Care Date: 2006-08 Impact factor: 19.112
Authors: K S Polonsky; B D Given; L Hirsch; E T Shapiro; H Tillil; C Beebe; J A Galloway; B H Frank; T Karrison; E Van Cauter Journal: J Clin Invest Date: 1988-02 Impact factor: 14.808
Authors: Sudha S Shankar; Adrian Vella; Ralph H Raymond; Myrlene A Staten; Roberto A Calle; Richard N Bergman; Charlie Cao; Danny Chen; Claudio Cobelli; Chiara Dalla Man; Mark Deeg; Jennifer Q Dong; Douglas S Lee; David Polidori; R Paul Robertson; Hartmut Ruetten; Darko Stefanovski; Maria T Vassileva; Gordon C Weir; David A Fryburg Journal: Diabetes Care Date: 2016-07-12 Impact factor: 19.112
Authors: Ron T Varghese; Chiara Dalla Man; Anu Sharma; Ivan Viegas; Cristina Barosa; Catia Marques; Meera Shah; John M Miles; Robert A Rizza; John G Jones; Claudio Cobelli; Adrian Vella Journal: J Clin Endocrinol Metab Date: 2016-09-07 Impact factor: 5.958
Authors: Marcello C Laurenti; Chiara Dalla Man; Ron T Varghese; James C Andrews; Robert A Rizza; Aleksey Matveyenko; Giuseppe De Nicolao; Claudio Cobelli; Adrian Vella Journal: JCI Insight Date: 2020-04-09
Authors: Anu Sharma; Ron T Varghese; Meera Shah; Chiara Dalla Man; Claudio Cobelli; Robert A Rizza; Kent R Bailey; Adrian Vella Journal: J Clin Endocrinol Metab Date: 2018-01-01 Impact factor: 5.958
Authors: Anu Sharma; Marcello C Laurenti; Chiara Dalla Man; Ron T Varghese; Claudio Cobelli; Robert A Rizza; Aleksey Matveyenko; Adrian Vella Journal: Diabetologia Date: 2017-05-27 Impact factor: 10.122
Authors: Ron T Varghese; Chiara Dalla Man; Marcello C Laurenti; Francesca Piccinini; Anu Sharma; Meera Shah; Kent R Bailey; Robert A Rizza; Claudio Cobelli; Adrian Vella Journal: Diabetes Obes Metab Date: 2017-09-27 Impact factor: 6.577
Authors: Meera Shah; Ron T Varghese; John M Miles; Francesca Piccinini; Chiara Dalla Man; Claudio Cobelli; Kent R Bailey; Robert A Rizza; Adrian Vella Journal: Diabetes Date: 2015-11-02 Impact factor: 9.461